Skip to content

Postnatal Choline Supplementation in Children With Prenatal Alcohol Exposure

Postnatal Choline Supplementation in Children With Prenatal Alcohol Exposure

Status
Completed
Phases
Phase 1Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01149538
Enrollment
60
Registered
2010-06-23
Start date
2010-07-31
Completion date
2014-09-30
Last updated
2016-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fetal Alcohol Spectrum Disorders, Fetal Alcohol Syndrome, Partial Fetal Alcohol Syndrome, Alcohol Related Neurodevelopmental Disorder, Prenatal Alcohol Exposure

Keywords

FASD, FAS, Alcohol, Prenatal Alcohol

Brief summary

The purpose of this study is to determine if choline bitartrate can be administered daily to children with prenatal alcohol exposure, ages 2.5 to 5, as a potential treatment for brain development and cognitive functioning.

Interventions

Choline bitartrate 500 mg. daily, administered in fruit-flavored drink mix.

DIETARY_SUPPLEMENTPlacebo for choline bitartrate

Placebo for choline bitartrate, administered daily in fruit-flavored drink mix.

Sponsors

National Institute on Alcohol Abuse and Alcoholism (NIAAA)
CollaboratorNIH
University of Minnesota
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
2 Years to 5 Years
Healthy volunteers
No

Inclusion criteria

* Available parent or legal guardian capable of participating in informed consent process * Documented history of heavy prenatal alcohol exposure (self-report, social service records, or adoption records) or presence of facial dysmorphology characteristic of FASD or both * Evidence of cognitive deficit in at least one neurocognitive domain

Exclusion criteria

* History of neurological condition (ex. epilepsy, cerebral palsy, traumatic brain injury) * History of medical condition known to affect brain function * History of other neurodevelopmental disorder (ex. autism, down syndrome) * History of very low birthweight (\<1500 grams) * History of prenatal exposure to drugs other than alcohol, nicotine, and caffeine

Design outcomes

Primary

MeasureTime frameDescription
Side Effects of Choline BitartrateBaseline, 6 months, & 9 monthsSide effects of choline bitartrate will be monitored by the study physician and the P.I. with physical examinations and telephone contact.
Mullen Scales of Early Learning - Early Learning CompositeBaseline and 9 monthsThe Mullen Scales of Early Learning is a measure of global cognitive development and is a primary outcome measure. The Early Learning Composite is the total score for this measure. It is a scaled score with a mean of 100 and a standard deviation of 15 (higher scores indicate better global cognitive status; average range is 85-115; Impaired range is 70 or below; full range is typically 50 - 150, although minimum and maximum scores are dependent on age). See the Mullen Scales reference manual for more psychometric details.

Secondary

MeasureTime frameDescription
Elicited Imitation Task MemoryBaseline, 6 months, and 9 monthsThe Elicited Imitation (EI) paradigm (P.J. Bauer, 1989, Dev. Psychology) was used to measure memory in the participants at baseline, 6 months, and 9 months. The measures were items recalled after a delay (delayed items) and pairs of items recalled after a delay (delayed pairs). The sample was split by age in the analysis (young vs. old) as reflected in the outcome data. Outcome data measures included here are the slopes of the regression lines reflecting change over the three timepoints, controlling for immediate memory performance on the EI task.The slopes are given, as opposed to the raw scores, because these were the values used in the growth curve analyses. Details of these analyses are included in Wozniak et al. (2015) AJCN, doi:10.3945/ajcn.114.099168. NOTE that the means presented below represent the simple slopes that estimate the change in task performance (% of items correct) per 6-month unit of time. To estimate change in task performance over 9 months, multiply by 1.5.
Evoked Response Potentials MicrovoltsBaseline, 6 months, and 9 monthsEvoked response potentials were measured for the memory task. Frontal positive slow-wave potential negative component amplitude data are included.
Evoked Response Potential - Negative Component LatencyBaseline, 6 months, and 9 monthsEvoked Response Potential - negative component latency data are included.

Countries

United States

Participant flow

Participants by arm

ArmCount
Choline Bitartrate
Choline Bitartrate supplementation Choline bitartrate: Choline bitartrate 500 mg. daily, administered in fruit-flavored drink mix.
31
Placebo
Placebo for choline bitartrate supplementation Placebo for choline bitartrate: Placebo for choline bitartrate, administered daily in fruit-flavored drink mix.
29
Total60

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyLost to Follow-up01
Overall StudyWithdrawal by Subject53

Baseline characteristics

CharacteristicCholine BitartratePlaceboTotal
Age, Continuous3.79 years
STANDARD_DEVIATION 0.8
3.92 years
STANDARD_DEVIATION 0.76
3.855 years
STANDARD_DEVIATION 0.78
Gender
Female
19 Participants19 Participants38 Participants
Gender
Male
12 Participants10 Participants22 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
15 / 3113 / 29
serious
Total, serious adverse events
0 / 310 / 29

Outcome results

Primary

Mullen Scales of Early Learning - Early Learning Composite

The Mullen Scales of Early Learning is a measure of global cognitive development and is a primary outcome measure. The Early Learning Composite is the total score for this measure. It is a scaled score with a mean of 100 and a standard deviation of 15 (higher scores indicate better global cognitive status; average range is 85-115; Impaired range is 70 or below; full range is typically 50 - 150, although minimum and maximum scores are dependent on age). See the Mullen Scales reference manual for more psychometric details.

Time frame: Baseline and 9 months

Population: Including those with partial completion (drop-outs and lost-to-followup).

ArmMeasureGroupValue (MEAN)Dispersion
Choline BitartrateMullen Scales of Early Learning - Early Learning Composite9-month follow-up87.1 units on a scaleStandard Deviation 16.4
Choline BitartrateMullen Scales of Early Learning - Early Learning CompositeBaseline83.2 units on a scaleStandard Deviation 13.7
PlaceboMullen Scales of Early Learning - Early Learning CompositeBaseline84.3 units on a scaleStandard Deviation 21.4
PlaceboMullen Scales of Early Learning - Early Learning Composite9-month follow-up89.6 units on a scaleStandard Deviation 21.6
Primary

Side Effects of Choline Bitartrate

Side effects of choline bitartrate will be monitored by the study physician and the P.I. with physical examinations and telephone contact.

Time frame: Baseline, 6 months, & 9 months

Population: Children with fetal alcohol spectrum disorders receiving either choline or placebo for 9 months

ArmMeasureGroupValue (NUMBER)
Choline BitartrateSide Effects of Choline Bitartrate9 month cardiovascular1 participants
Choline BitartrateSide Effects of Choline BitartrateBaseline respiratory problems6 participants
Choline BitartrateSide Effects of Choline BitartrateBaseline musculoskeletal problems0 participants
Choline BitartrateSide Effects of Choline BitartrateBaseline skin problems6 participants
Choline BitartrateSide Effects of Choline Bitartrate6 month skin problems6 participants
Choline BitartrateSide Effects of Choline BitartrateBaseline energy level problems8 participants
Choline BitartrateSide Effects of Choline Bitartrate6 month energy level problems8 participants
Choline BitartrateSide Effects of Choline Bitartrate9 months energy level problems8 participants
Choline BitartrateSide Effects of Choline BitartrateBaseline pain3 participants
Choline BitartrateSide Effects of Choline Bitartrate6 month pain3 participants
Choline BitartrateSide Effects of Choline Bitartrate9 month pain3 participants
Choline BitartrateSide Effects of Choline Bitartrate9 month skin problems6 participants
Choline BitartrateSide Effects of Choline BitartrateBaseline Ear Nose Throat problems1 participants
Choline BitartrateSide Effects of Choline Bitartrate6 month Ear Nose Throat problems1 participants
Choline BitartrateSide Effects of Choline Bitartrate9 month Ear Nose Throat problems1 participants
Choline BitartrateSide Effects of Choline BitartrateBaseline headaches/dizziness2 participants
Choline BitartrateSide Effects of Choline Bitartrate6 month headaches/dizziness2 participants
Choline BitartrateSide Effects of Choline Bitartrate9 month headaches/dizziness2 participants
Choline BitartrateSide Effects of Choline BitartrateBaseline vision problems2 participants
Choline BitartrateSide Effects of Choline Bitartrate6 month vision problems0 participants
Choline BitartrateSide Effects of Choline Bitartrate9 month vision problems0 participants
Choline BitartrateSide Effects of Choline BitartrateBaseline cardiovascular1 participants
Choline BitartrateSide Effects of Choline Bitartrate6 month cardiovascular1 participants
Choline BitartrateSide Effects of Choline Bitartrate6 month respiratory problems6 participants
Choline BitartrateSide Effects of Choline Bitartrate9 month respiratory problems6 participants
Choline BitartrateSide Effects of Choline BitartrateBaseline gastrointestinal problems18 participants
Choline BitartrateSide Effects of Choline Bitartrate6 month gastrointestinal problems18 participants
Choline BitartrateSide Effects of Choline Bitartrate9 month gastrointestinal problems18 participants
Choline BitartrateSide Effects of Choline BitartrateBaseline genitourinary problems4 participants
Choline BitartrateSide Effects of Choline Bitartrate6 month genitourinary problems4 participants
Choline BitartrateSide Effects of Choline Bitartrate9 month genitourinary problems4 participants
Choline BitartrateSide Effects of Choline Bitartrate6 month musculoskeletal problems0 participants
Choline BitartrateSide Effects of Choline Bitartrate9 month musculoskeletal problems0 participants
Choline BitartrateSide Effects of Choline Bitartrate6 month neurologic/psychiatric problems11 participants
Choline BitartrateSide Effects of Choline Bitartrate9 month neurologic/psychiatric problems11 participants
Choline BitartrateSide Effects of Choline BitartrateBaseline neurologic/psychiatric problems11 participants
Choline BitartrateSide Effects of Choline BitartrateBaseline allergic problems2 participants
Choline BitartrateSide Effects of Choline Bitartrate6 month allergic problems0 participants
Choline BitartrateSide Effects of Choline Bitartrate9 month allergic problems0 participants
PlaceboSide Effects of Choline Bitartrate6 month vision problems2 participants
PlaceboSide Effects of Choline Bitartrate9 month cardiovascular1 participants
PlaceboSide Effects of Choline BitartrateBaseline allergic problems3 participants
PlaceboSide Effects of Choline Bitartrate9 month genitourinary problems8 participants
PlaceboSide Effects of Choline Bitartrate9 month vision problems2 participants
PlaceboSide Effects of Choline BitartrateBaseline musculoskeletal problems1 participants
PlaceboSide Effects of Choline Bitartrate6 month genitourinary problems8 participants
PlaceboSide Effects of Choline BitartrateBaseline skin problems6 participants
PlaceboSide Effects of Choline BitartrateBaseline cardiovascular1 participants
PlaceboSide Effects of Choline Bitartrate9 month neurologic/psychiatric problems9 participants
PlaceboSide Effects of Choline BitartrateBaseline energy level problems10 participants
PlaceboSide Effects of Choline Bitartrate6 month cardiovascular1 participants
PlaceboSide Effects of Choline Bitartrate6 month energy level problems9 participants
PlaceboSide Effects of Choline BitartrateBaseline respiratory problems6 participants
PlaceboSide Effects of Choline Bitartrate9 months energy level problems9 participants
PlaceboSide Effects of Choline Bitartrate9 month allergic problems3 participants
PlaceboSide Effects of Choline BitartrateBaseline pain4 participants
PlaceboSide Effects of Choline Bitartrate6 month respiratory problems6 participants
PlaceboSide Effects of Choline Bitartrate6 month pain4 participants
PlaceboSide Effects of Choline Bitartrate6 month musculoskeletal problems1 participants
PlaceboSide Effects of Choline Bitartrate9 month pain4 participants
PlaceboSide Effects of Choline Bitartrate6 month skin problems5 participants
PlaceboSide Effects of Choline Bitartrate9 month respiratory problems6 participants
PlaceboSide Effects of Choline Bitartrate9 month skin problems5 participants
PlaceboSide Effects of Choline BitartrateBaseline neurologic/psychiatric problems9 participants
PlaceboSide Effects of Choline BitartrateBaseline Ear Nose Throat problems0 participants
PlaceboSide Effects of Choline BitartrateBaseline gastrointestinal problems14 participants
PlaceboSide Effects of Choline Bitartrate6 month Ear Nose Throat problems0 participants
PlaceboSide Effects of Choline Bitartrate9 month musculoskeletal problems1 participants
PlaceboSide Effects of Choline Bitartrate9 month Ear Nose Throat problems1 participants
PlaceboSide Effects of Choline Bitartrate6 month gastrointestinal problems11 participants
PlaceboSide Effects of Choline BitartrateBaseline headaches/dizziness2 participants
PlaceboSide Effects of Choline Bitartrate6 month allergic problems3 participants
PlaceboSide Effects of Choline Bitartrate6 month headaches/dizziness2 participants
PlaceboSide Effects of Choline Bitartrate9 month gastrointestinal problems11 participants
PlaceboSide Effects of Choline Bitartrate9 month headaches/dizziness2 participants
PlaceboSide Effects of Choline Bitartrate6 month neurologic/psychiatric problems9 participants
PlaceboSide Effects of Choline BitartrateBaseline vision problems2 participants
PlaceboSide Effects of Choline BitartrateBaseline genitourinary problems9 participants
Secondary

Elicited Imitation Task Memory

The Elicited Imitation (EI) paradigm (P.J. Bauer, 1989, Dev. Psychology) was used to measure memory in the participants at baseline, 6 months, and 9 months. The measures were items recalled after a delay (delayed items) and pairs of items recalled after a delay (delayed pairs). The sample was split by age in the analysis (young vs. old) as reflected in the outcome data. Outcome data measures included here are the slopes of the regression lines reflecting change over the three timepoints, controlling for immediate memory performance on the EI task.The slopes are given, as opposed to the raw scores, because these were the values used in the growth curve analyses. Details of these analyses are included in Wozniak et al. (2015) AJCN, doi:10.3945/ajcn.114.099168. NOTE that the means presented below represent the simple slopes that estimate the change in task performance (% of items correct) per 6-month unit of time. To estimate change in task performance over 9 months, multiply by 1.5.

Time frame: Baseline, 6 months, and 9 months

Population: Young choline group (n=17); Young placebo group (n=13); Old choline group (n=14); Old placebo group (n=16).

ArmMeasureGroupValue (MEAN)Dispersion
Choline BitartrateElicited Imitation Task MemoryDelayed-Items-Young14.24 SlopeStandard Error 3.84
Choline BitartrateElicited Imitation Task MemoryDelayed-Items-Old-.71 SlopeStandard Error 3.98
Choline BitartrateElicited Imitation Task MemoryDelayed-Pairs-Young18.97 SlopeStandard Error 3.65
Choline BitartrateElicited Imitation Task MemoryDelayed-Pairs-Old2.69 SlopeStandard Error 3.79
Choline BitartrateElicited Imitation Task MemoryImmed-Items-Young8.48 SlopeStandard Error 4.23
Choline BitartrateElicited Imitation Task MemoryImmed-Items-Old2.59 SlopeStandard Error 4.36
Choline BitartrateElicited Imitation Task MemoryImmed-Pairs-Young8.75 SlopeStandard Error 4.45
Choline BitartrateElicited Imitation Task MemoryImmed-Pairs-Old11.46 SlopeStandard Error 4.61
PlaceboElicited Imitation Task MemoryImmed-Pairs-Old5.50 SlopeStandard Error 4.46
PlaceboElicited Imitation Task MemoryDelayed-Items-Young4.43 SlopeStandard Error 4.04
PlaceboElicited Imitation Task MemoryImmed-Items-Young13.72 SlopeStandard Error 4.41
PlaceboElicited Imitation Task MemoryDelayed-Items-Old4.23 SlopeStandard Error 3.9
PlaceboElicited Imitation Task MemoryImmed-Pairs-Young20.01 SlopeStandard Error 4.8
PlaceboElicited Imitation Task MemoryDelayed-Pairs-Young10.39 SlopeStandard Error 4
PlaceboElicited Imitation Task MemoryImmed-Items-Old3.89 SlopeStandard Error 4.24
PlaceboElicited Imitation Task MemoryDelayed-Pairs-Old7.79 SlopeStandard Error 3.73
Secondary

Evoked Response Potential - Negative Component Latency

Evoked Response Potential - negative component latency data are included.

Time frame: Baseline, 6 months, and 9 months

Population: Children with FASD who were administered Evoked Response Potential test and provided usable data (choline and placebo arms)

ArmMeasureGroupValue (MEAN)Dispersion
Choline BitartrateEvoked Response Potential - Negative Component LatencyFrontal Neg Component Latency at baseline2.23 MillisecondsStandard Deviation 43.96
Choline BitartrateEvoked Response Potential - Negative Component LatencyFrontal Neg Component at 6 months32.45 MillisecondsStandard Deviation 60.31
Choline BitartrateEvoked Response Potential - Negative Component LatencyFrontal Neg Component at 9 months-4.00 MillisecondsStandard Deviation 42.3
PlaceboEvoked Response Potential - Negative Component LatencyFrontal Neg Component at 9 months-3.03 MillisecondsStandard Deviation 79.62
PlaceboEvoked Response Potential - Negative Component LatencyFrontal Neg Component Latency at baseline5.35 MillisecondsStandard Deviation 60.21
PlaceboEvoked Response Potential - Negative Component LatencyFrontal Neg Component at 6 months-4.28 MillisecondsStandard Deviation 55.22
Secondary

Evoked Response Potentials Microvolts

Evoked response potentials were measured for the memory task. Frontal positive slow-wave potential negative component amplitude data are included.

Time frame: Baseline, 6 months, and 9 months

Population: Children with FASD who were administered Evoked Response Potential test and provided usable date (choline and placebo arms)

ArmMeasureGroupValue (MEAN)Dispersion
Choline BitartrateEvoked Response Potentials MicrovoltsFrontal Positive Slow Wave (PSW) - 6 months-1.04 MircovoltsStandard Deviation 4.58
Choline BitartrateEvoked Response Potentials MicrovoltsFrontal Positive Slow Wave (PSW) - Baseline-2.05 MircovoltsStandard Deviation 5.49
Choline BitartrateEvoked Response Potentials MicrovoltsFrontal Positive Slow Wave (PSW) - 9 months-0.26 MircovoltsStandard Deviation 5.01
Choline BitartrateEvoked Response Potentials MicrovoltsFrontal Neg Component Amplitude - Baseline-2.53 MircovoltsStandard Deviation 5.66
Choline BitartrateEvoked Response Potentials MicrovoltsFrontal Neg Component Amplitude - 6 months1.22 MircovoltsStandard Deviation 5.46
Choline BitartrateEvoked Response Potentials MicrovoltsFrontal Neg Component Amplitude - 9 months0.35 MircovoltsStandard Deviation 5.53
PlaceboEvoked Response Potentials MicrovoltsFrontal Neg Component Amplitude - 6 months-0.84 MircovoltsStandard Deviation 4.94
PlaceboEvoked Response Potentials MicrovoltsFrontal Positive Slow Wave (PSW) - 6 months-1.03 MircovoltsStandard Deviation 3.48
PlaceboEvoked Response Potentials MicrovoltsFrontal Neg Component Amplitude - Baseline0.62 MircovoltsStandard Deviation 7.56
PlaceboEvoked Response Potentials MicrovoltsFrontal Positive Slow Wave (PSW) - Baseline0.57 MircovoltsStandard Deviation 7.24
PlaceboEvoked Response Potentials MicrovoltsFrontal Neg Component Amplitude - 9 months-1.37 MircovoltsStandard Deviation 5.08
PlaceboEvoked Response Potentials MicrovoltsFrontal Positive Slow Wave (PSW) - 9 months-1.41 MircovoltsStandard Deviation 5.23

Source: ClinicalTrials.gov · Data processed: Mar 15, 2026